Posts in Knowledge Base

Clinical Evaluation and Clinical Evidence Under the MDR

The MDR raised the bar on clinical evidence sharply. “It worked under the old directive” is no longer enough — every device now needs a[…]

Technical Documentation and the GSPR Under the MDR

The technical documentation is the evidence file that proves a device is safe and performs as intended. It is what a notified body assesses, what[…]

Medical Device Classification Under the MDR

Under the EU Medical Device Regulation, everything starts with classification. Get the risk class right and the whole route to market follows logically; get it[…]

Choosing Your Route to Market: EU Marketing Authorisation Procedures Explained

For any company bringing a medicine to Europe, one of the earliest and most consequential decisions is procedural rather than scientific: which marketing authorisation route[…]

The PSMF: Keeping Your Pharmacovigilance House in Order

The Pharmacovigilance System Master File is the single document that describes how a company keeps its medicines safe. When an inspector arrives, it is often[…]

Nitrosamines: From Crisis Response to Business as Usual

What began as an urgent, industry-wide safety review of nitrosamine impurities has settled into a permanent feature of pharmaceutical quality management. The call-for-review deadlines have[…]

ATMPs: The Regulatory Path for Advanced Therapies

Cell and gene therapies are among the most promising — and most complex — medicines in development. Advanced therapy medicinal products follow a dedicated regulatory[…]

Serialisation and the Falsified Medicines Directive in Greece

Every prescription pack in Europe now carries a unique code and a tamper-evident seal. For companies supplying Greece, the country’s late arrival to this system[…]

How Medicines Are Priced in Greece: A Practical Guide

Pricing a medicine in Greece is not a negotiation in the usual sense — it is largely a calculation, driven by the prices of other[…]

Real-World Evidence: From Nice-to-Have to Decision-Maker

The randomised controlled trial remains the gold standard — but it no longer stands alone. Real-world evidence is increasingly shaping both regulatory approval and reimbursement[…]